Infectious Diseases

Antivirals, antibiotics, antifungals, and vaccines targeting bacterial, viral, and parasitic infections.

Companies

Pipeline Drugs

3388

Key People

2764

Infectious Diseases Pipeline (3388 drugs)

Commercial: 679Pre-clinical: 457Preclinical: 301Approved: 195Phase 1: 153Development: 152Phase 2: 140Phase 3: 110Research: 106Discovery: 65Marketed: 64Phase 1/2: 37Development/Commercial: 34Phase III: 24Approved/Commercial: 24Clinical: 21Launched: 21Discovery/Preclinical: 21Research/Pre-clinical: 18Phase 2/3: 17Commercial/Development: 16Service: 16Not Specified: 15Pre‑clinical: 14Phase 1b: 13Market: 13Phase 2b: 12Research-Use Only: 12Unknown: 12Development/Validation: 12Research/Development: 12Phase 2a: 10Pre-clinical/Research: 10commercial: 9N/A: 9Not specified: 9Research Use Only: 8DiscoverY: 8Commercial Launch: 7Not Disclosed: 7Discovery/Pre-clinical: 7Pre-commercial: 7Pre-clinical/Development: 7IVD: 7Phase 1b/2: 6Clinical Validation: 6Phase II: 6RUO: 6Preclinical/Discovery: 5Research-Use-Only: 5Phase 2b/3: 5Commercial (LDT): 5In Development: 5Marketed (Global): 5BLA Submitted: 5Process Scale‑up: 4R&D: 4Reference Standard: 4Not Applicable: 4Phase 2B: 4Commercial (CE Mark): 4Commercial Model: 4Service Offering: 4Phase I: 4Pre-clinical/Phase 1: 4Phase 3 / Registration: 4Research/Validation: 4Platform/Partnership: 4preclinical: 4Commercial (EUA): 3Commercial Development: 3Clinical Trial: 3Preclinical/Development: 3Clinical Investigation: 3Research/Discovery: 3Clinical Development: 3NDA Submitted: 3Platform Development: 3Poised for Clinical: 3Pre-IND: 3All Phases: 3Market-ready: 3Feasibility: 3Commercial & Development: 3Pre-clinical/Clinical: 3N/A - Service: 3Preclinical/Phase 1/2: 3LDT: 3Validation: 3Preclinical/Phase 1: 3Development/Accreditation: 3Not Disclosed/Partner Dependent: 3Commercial Expansion: 3Preclinical through Commercial: 3Proof of Concept: 3NDA Filed: 3Regulatory Review: 3Commercial/Platform: 3Research Use: 3FDA-Cleared: 3Phase 1b/2a: 3Early Preclinical: 2Preclinical Research: 2Pilot: 2Pre-clinical/R&D: 2Phase 2/Phase 3: 2Breakthrough Device Designation: 2Research/Service: 2Pre-market: 2Pre-launch: 2Pre-clinical/Clinical Validation: 2Validation/Commercial: 2Pre-Clinical: 2Commercial (FDA EUA): 2NDA: 2Post-Market: 2Research & Development: 2Commercial (RUO): 2Proof-of-Concept: 2Assay Development: 2Service/Commercial: 2Development/Pilot: 2Assay Development/Validation: 2Development/Commercialization: 2Filed: 2Clinical (Phase not specified): 2RUO Commercial: 2Development/Regulatory: 2Lifecycle Management: 2Phase 3 (planned): 2ANDA Filed/Approved: 2IND Planned: 2Clinical use (TFDA‑approved LDT): 2Commercial (CE‑certified): 1Pre‑clinical/Phase 1: 1Approved (EUA): 1Commercial (Approved): 1Clinical Trial (Phase not specified): 1ANDA Filed / Development: 1ANDA Pending / Development: 1Marketed / Line Extensions: 1Pre-commercial/Development: 1Phase Ib/IIa: 1Phase 3 / Development: 1Phase III/Commercial: 1Development & Validation: 1Continuous Development: 1Development & Expansion: 1Assay Menu Expansion: 1Integrated Solution: 1Solution: 1Phase 2a/b Challenge: 1Clinical stage (potential acquisition): 1Not Disclosed (Likely Preclinical/Early Clinical): 1Research / Early Clinical: 1Approved (Japan): 1Commercial (in China): 1Continuous R&D: 1Concept: 1Approved (NPIP): 1Platform Technology: 1Research & Regulated Studies: 1Phase 1a/1b: 1Research Use / Assay Development: 1Early Feasibility / Safety: 1Marketed (EU): 1Commercial & Expansion: 1Development / Early Commercial: 1ANVISA Submission/Commercial: 1Phase 2a/2b: 1Preclinical/Phase 1 (ex-China): 1Approved (FDA De Novo): 1Clinical Stage: 1Phase 1-3: 1ANDA Development/Commercial: 1Implementation: 1Strategic Development: 1Research/Exploratory: 1Pre-clinical (in vitro studies planned): 1Pre-market Approval: 1Commercial / Clinical Development: 1Candidate-Enabled: 1Development Stage (Pre-clinical): 1Development Stage: 1ANDA Filed/Pre-approval: 1Service Platform: 1Research/Proof-of-Concept: 1Approved/EUA: 1Process Development/Technology Transfer: 1Not Disclosed (Likely Pre-clinical/Early Clinical): 1Launching: 1Clinical (phase unspecified): 1Partnership/Launch: 1Platform: 1FDA Submission: 1Development/Deployment: 1Development/Launch: 1Developed (LDT): 1Device Development: 1Feasibility Study: 1Research Study: 1Various Phases (I-III): 1LDT/Service: 1Proof of concept: 1Phase 2b/Phase 3 Prep: 1Development/Scale-up: 1Pre-clinical / Phase 1 (implied): 1Not Applicable (Device): 1Commercial / Line Extension: 1Discovery/Partnership: 1Approved/RUO: 1Phase 1/2a: 1Commercial / Generic Development: 1Early Access: 1ANDA Approved: 1ANDA Development/Filing: 1Phase 2 (based on prior studies; current development stage unclear): 1Phase 2 (planned): 1Not Specified (Orphan Designated): 1Early Commercial/Research: 1Pre-clinical/Early Clinical: 1Development & Regulatory: 1Research/Platform Development: 1Clinically Validated: 1Early Discovery: 1Completed R&D: 1Phase 1B: 1Development/Commercial Launch: 1Deployed: 1Clinical (Partnered): 1Investigational Use Only: 1Exploratory: 1Pre-commercial/Regulatory Review: 1Research/Design: 1Phase I-IV: 1IVDR-Compliant Launch: 1Pre-clinical/Clinical (Phase not specified): 1NA: 1Partnership/Development: 1Phase I/IIa: 1Research/Development & Commercial (EUA for COVID-19): 1Development for FDA Approval: 1IND Filed: 1Licensed/Orphan Designation: 1Phase 2/Spin-out: 1Research Use/Commercial: 1Integration: 1Pre-clinical/Clinically Ready: 1Phase 1-4 (as component): 1Research / Pre-clinical: 1Approved (ex-US) / Investigational (US): 1First-in-Human (under IDE): 1Discovery/Validation: 1Lead Optimization: 1Clinical Study: 1Commercial/Research: 1Diagnostic Development: 1Commercial/Implementation: 1Development/Launched: 1Phase 2 (next-gen): 1Pre-clinical (based on prior clinical experience): 1Commercial (World's First Claim): 1Advanced Development: 1CE-IVD: 1Phase 4: 1Pivotal: 1Service Commercial: 1IND filed: 1Post-Market Studies: 1Registration/Clinical: 1Commercial (Facility Operational): 1Varies by Partner: 1Commercial (as service): 1Pre-clinical/Commercial: 1Development Completed: 1Development/CE Marking: 1Commercial/Market Expansion: 1R&D/Validation: 1Partnership/Regulatory: 1Phase 1/Phase 2: 1Regulatory Review (EMA): 1Not Disclosed (Likely Preclinical/Phase 1): 1Not Disclosed (Research/Preclinical): 1Various: 1Preclinical/Phase I: 1Platform/Product: 1Research/Platform: 1RUO/Clinical Research: 1IVD/CE-Marked: 1RUO / Development: 1Clinical Development (phase unspecified): 1Pre-clinical/Discovery: 1Product Validation: 1Development/Commercial Optimization: 1Late-stage Development: 1Discovery/Research: 1FDA‑EUA: 1CE‑Mark: 1Commercial (research use): 1CE‑marked / FDA‑clearance pending: 1Preclinical (Mouse Studies): 1IND Accepted: 1IND: 1Phase 1/2 completed, Phase 2b upcoming: 1Commercial (China): 1Pre-registration: 1Preclinical to Phase 2: 1Marketed/Clinical: 1Research to Clinical: 1Phase II/III: 1Application Submitted: 1BE Studies / Scale-up: 1Preclinical / Early Development: 1Formulation Development: 1Commercial / Development: 1Clinical/Commercial: 1NDA Resubmitted: 1Marketed/Development: 1Early Development: 1Phase III / NDA: 1Licensed: 1Registration: 1Multiple Phases 1/2: 1Regulatory Submission: 1Commercial / Regulatory Expansion: 1Launch: 1Pre-Clinical/Exploratory: 1Market Expansion: 1Discovery/Development: 1IVD Submission: 1Regulatory/Commercial: 1Phase not specified (Class 1 New Drug): 1Not specified (API/Formulation): 1Phase 1/2 (Inferred): 1Phase 1 (Inferred): 1CLIA LDT: 1Authorized: 1Approved in China: 1IND Cleared: 1Phase 3 / NDA Submitted: 1Not Specified (Preclinical/Research): 1Phase I to Phase III: 1Not specified (likely clinical): 1FDA 510(k) Submission: 1Clinical Research / LDT: 1Phase 2 Ready: 1Phase 1/IIa: 1Preclinical (IND granted per timeline): 1Pre‑clinical development: 1Preclinical/Early Clinical: 1Phase 1 / Proof-of-Concept: 1Phase 2-ready: 1Phase 2/1b: 1Phase I/II (implied): 1Prescription Product: 1

Drug	Company	Indication	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Rheumatoid Arthritis	Development	Active
Biological Age Predictor	Age Labs	Aging Assessment	Development	Active
COVID-19 Severity Prediction Test	Age Labs	COVID-19	Development	Active
Herceptin (Trastuzumab) Biosimilar	NeuClone	HER2‑positive Breast Cancer	Phase 1	Active
Stelara (Ustekinumab) Biosimilar	NeuClone	Psoriasis / Crohn's Disease	Phase 1	Active
Perjeta (Pertuzumab) Biosimilar	NeuClone	HER2‑positive Breast Cancer	Process Scale‑up	Active
Opdivo (Nivolumab) Biosimilar	NeuClone	Various Cancers (PD‑1 inhibitor)	Process Scale‑up	Active
Keytruda (Pembrolizumab) Biosimilar	NeuClone	Various Cancers (PD‑1 inhibitor)	Process Scale‑up	Active
Prolia/XGEVA (Denosumab) Biosimilar	NeuClone	Bone Metastases / Osteoporosis	Process Scale‑up	Active
Humira (Adalimumab) Biosimilar	NeuClone	Autoimmune Diseases	Early Preclinical	Active
Synagis (Palivizumab) Biosimilar	NeuClone	RSV Prophylaxis	Early Preclinical	Active
PanCytoVir™ (oral probenecid)	TrippBio	COVID-19	Phase 2	Active
Oncology Vaccine Program	CHAIN Biotech	Oncology (unspecified)	Pre-clinical	Active
Anti-infective Vaccine Program	CHAIN Biotech	Infectious Diseases (unspecified)	Pre-clinical	Active
BIT225	Biotron	HIV‑1	Phase 2	Active
Preclinical Program	Biotron	Dengue Virus	Preclinical	Active
PENAO	Beroni Group	Solid Tumors (ovarian, breast, pancreatic)	Preclinical	Active
Immune Cell Therapy Platform	Beroni Group	Cancer & Age‑related Degeneration	Preclinical	Active
SARS‑CoV‑2 Antigen Test Kit	Beroni Group	Infectious Disease Diagnosis	Commercial (CE‑certified)	Active
Nasovac‑S™	BioDiem	Seasonal Influenza	Commercial	Active
DeFluvac	BioDiem	Seasonal Influenza	Commercial	Active
Cell‑based LAIV platform	BioDiem	Seasonal & Pandemic Influenza	Pre‑clinical/Phase 1	Active
ALS-4	Aptorum Group	Staphylococcus aureus infections (including MRSA)	Preclinical	Active
NCL-195	Aptorum Group	Neuroblastoma and other solid tumors	Preclinical	Active
Talis One COVID-19 Test	Talis Biomedical	SARS-CoV-2 Infection	Commercial (EUA)	Terminated
Talis One Respiratory Panel	Talis Biomedical	COVID-19, Influenza, RSV	Development	Terminated
Talis One STI Panel	Talis Biomedical	Chlamydia, Gonorrhea	Development	Terminated
Sanoosa‑001	Sanoosa	Chronic Inflammatory Disease	Preclinical	Active
Sanoosa‑002	Sanoosa	Solid Tumor Oncology	Preclinical	Active
Sanoosa‑003	Sanoosa	COVID‑19 Antiviral	Preclinical	Active
EasyScreen™ Gastrointestinal Parasite Detection Kit	Genetic Signatures	Gastrointestinal parasites	Commercial	Active
EasyScreen™ Respiratory Virus Panel	Genetic Signatures	Respiratory viral infections	Commercial	Active
EasyScreen™ Enteric Pathogen Panel	Genetic Signatures	Enteric bacterial and viral pathogens	Commercial	Active
Logix Smart COVID-19 Test	Co-Diagnostics	SARS-CoV-2 Infection	Commercial	Marketed
Tuberculosis Detection & Resistance	Co-Diagnostics	Mycobacterium tuberculosis	Commercial/Development	Active
Hepatitis B & C Tests	Co-Diagnostics	HBV/HCV Infection	Commercial/Development	Active
HPV Test	Co-Diagnostics	High-risk Human Papillomavirus	Commercial/Development	Active
Malaria Test	Co-Diagnostics	Plasmodium Infection	Commercial	Marketed
Zika/Dengue/Chikungunya Multiplex	Co-Diagnostics	Arbovirus Infection	Development	Active
Respiratory Multiplex Panels	Co-Diagnostics	Influenza, RSV, etc.	Development	Active
Opaganib (ABC294640)	RedHill Biopharma	COVID-19 (Severe Hospitalized)	Phase 2/3	Active
Opaganib	RedHill Biopharma	Prostate Cancer	Phase 2	Active
RHB-107 (Upamostat)	RedHill Biopharma	COVID-19 (Non-Hospitalized)	Phase 3	Active
RHB-107	RedHill Biopharma	Cancer (Solid Tumors)	Phase 1/2	Active
RHB-204	RedHill Biopharma	Pulmonary Nontuberculous Mycobacteria (NTM) Disease	Phase 3	Active
dl-3-n-Butylphthalide (NBP) Soft Capsules	cspc-pharmaceutical	Ischemic Stroke	Phase 3	Active (US trials with FDA orphan drug designation)
Benzonatate Soft Capsules	cspc-pharmaceutical	Cough Suppressant	Commercial	Marketed in US
Azithromycin Preparations	cspc-pharmaceutical	Bacterial Infections	Commercial	Marketed
Penem Preparations	cspc-pharmaceutical	Bacterial Infections	Commercial	Marketed
Various Penicillin/Cephalosporin Products	cspc-pharmaceutical	Bacterial Infections	Commercial	Marketed